This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Genest, J. Articles by Pedersen, T. R. Search for Related Content PubMed PubMed Citation Articles by Genest, J. Articles by Pedersen, T. R. Related Collections Secondary prevention Risk Factors Epidemiology Lipid and lipoprotein metabolism

(Circulation. 2003;107:2059.)
© 2003 American Heart Association, Inc.

Clinical Cardiology: New Frontiers

Prevention of Cardiovascular Ischemic Events

High-Risk and Secondary Prevention

Jacques Genest, MD; Terje R. Pedersen, MD

From the Cardiology Division, McGill University Health Center, Montreal, Canada (J.G.); and Aker Hospital, Oslo, Norway (T.R.P.).

Correspondence to Jacques Genest, MD, Director, Division of Cardiology, McGill University Health Center/Royal Victoria Hospital, 687 Pine Ave West, Montreal, QC, Canada H3A 1A1. E-mail jacques.genest@muhc.mcgill.ca

Key Words: atherosclerosis • prevention • lipoproteins • cholesterol

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Atherosclerosis is a chronic disease involving the coronary, carotid, and aorto-femoral vascular beds that represents the major cause of death worldwide.^1,2 Coronary artery disease (CAD) is the major cause of morbidity and mortality in the world. Efforts at preventing the clinical manifestations of atherosclerosis have yielded impressive results in the past 3 decades and constitute the major focus of the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)³ and the Joint Task Force of European and other Societies on Coronary Prevention.⁴ The primary prevention of CAD represents one of the most important aspects of preventive medicine today. The secondary prevention of CAD has become the major focus of healthcare teams dealing with cardiovascular medicine. "Secondary prevention" was initially designated for patients who had a myocardial infarction. More recently, the term has been used to encompass patients with objective evidence of coronary artery, cerebrovascular, or peripheral disease.³ With the realization that patients with diabetes had a prognosis at least as grave as patients with CAD,^5,6 the term secondary prevention has yielded its place for a more comprehensive strategy aimed at treating patients at high risk of CAD. These include patients with multiple risk factors, a 10-year risk of cardiovascular event >20%, diabetes (especially those with one additional cardiovascular risk factor), atherosclerotic vascular disease, and a previous myocardial infarction. This population thus represents the top stratum of cardiovascular risk and has a prognosis equivalent to or worse than post-myocardial infarction patients.

Over the past 15 years, clinical practice guidelines . . . [Full Text of this Article]

This article has been cited by other articles:

				X. Liu, J. A. Simpson, K. R. Brunt, C. A. Ward, S. R. R. Hall, R. T. Kinobe, V. Barrette, M. Y. Tse, S. C. Pang, A. S. Pachori, et al. Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H48 - H59. [Abstract] [Full Text] [PDF]

				J. B. Kostis, H. J. Kim, J. Rusnak, T. Casale, A. Kaplan, J. Corren, and E. Levy Incidence and Characteristics of Angioedema Associated With Enalapril Arch Intern Med, July 25, 2005; 165(14): 1637 - 1642. [Abstract] [Full Text] [PDF]

				J. Genest, R. McPherson, J. Frohlich, and G. Fodor The analysis by Manuel and colleagues creates controversy with headlines, not data Can. Med. Assoc. J., April 12, 2005; 172(8): 1033 - 1034. [Full Text] [PDF]

				J. A.C. Lima, M. Y. Desai, H. Steen, W. P. Warren, S. Gautam, and S. Lai Statin-Induced Cholesterol Lowering and Plaque Regression After 6 Months of Magnetic Resonance Imaging-Monitored Therapy Circulation, October 19, 2004; 110(16): 2336 - 2341. [Abstract] [Full Text] [PDF]

				C. von Birgelen, M. Hartmann, G. S. Mintz, K. G. van Houwelingen, N. Deppermann, A. Schmermund, D. Bose, H. Eggebrecht, T. Neumann, M. Gossl, et al. Relationship Between Cardiovascular Risk as Predicted by Established Risk Scores Versus Plaque Progression as Measured by Serial Intravascular Ultrasound in Left Main Coronary Arteries Circulation, September 21, 2004; 110(12): 1579 - 1585. [Abstract] [Full Text] [PDF]

				M. A. Denke Coadministration of Multidrug Therapy to Achieve Lipid Goals J Am Osteopath Assoc, September 1, 2004; 104(9_suppl): 17S - 22S. [Abstract] [Full Text] [PDF]